Cabazitaxel is an anticancer drug that inhibits the ability of cancer cells to divide properly. It makes the “skeleton” in some cancer cells very stiff, so the cells can no longer grow or divide. It is approved for treating advanced prostate cancer, but its use in this study is considered investigational.
In this study, researchers want to find the highest dose of cabazitaxel that can be given safely in children and teenagers with malignant tumors that are not responding to treatment with other therapies. The investigators will also assess the preliminary effectiveness of cabazitaxel against these tumors. Cabazitaxel is given intravenously (by vein).
This study is being conducted by the POETIC (Pediatric Oncology Experimental
Consortium) research group.